Opinion
Video
Author(s):
Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.
Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL
Camidge and Cooper on Finding Purpose and Embracing Nuance in Hospital Chaplaincy
CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML
Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
Wang Expands on the Continued Investigation of Targeted Therapies in Relapsed/Refractory AML
UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC